Jennifer Robinson: Improving Accessibility to PCSK9 Inhibitors One Year Later

Video

It was just one year ago when doctors were excited about being able to offer PCSK9 inhibitors to patients in the hopes of helping them lower their cholesterol. Since that time one considerable challenge they have faced is overcoming the cost of this new class of medication.

It was just one year ago when doctors were excited about being able to offer PCSK9 inhibitors to patients in the hopes of helping them lower their cholesterol. Since that time one considerable challenge they have faced is overcoming the cost of this new class of medication.

Jennifer G. Robinson, MD, MPH, from the University of Iowa Carver College of Medicine discussed this topic during the American College of Cardiology's annual meeting in Chicago. While the new treatments are newer and more advanced than previously available treatment options Robinson said she hoped to see the price come down in the future to make it available to a larger group of patients. Robinson said there is also work being done to find a similar treatment that would not require infusions or injections but that that work is still in the early stages of development.

Related Videos
HCPLive Five at ACC 2024 | Image Credit: HCPLive
Ankeet Bhatt, MD, MBA | Credit: X.com
Ankeet Bhatt, MD, MBA | Credit: X.com
Sara Saberi, MD | Credit: University of Michigan
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Albert Foa, MD, PhD | Credit: HCPLive
Veraprapas Kittipibul, MD | Credit: X.com
Heart Failure stock imagery. | Credit: Fotolia
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Maternal Hidradenitits Suppurativa Linked to Neonatal Mortality, Pediatric Hospitalization Risk
© 2024 MJH Life Sciences

All rights reserved.